Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com
HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com
COA 2025: Insight, Innovation, and Independent Strength

May 5th 2025

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Implications of Bundled Payments in Oncology
December 30th 2015

Implications of Bundled Payments in Oncology

What Are the Constructs of Value-Based Care?
December 30th 2015

What Are the Constructs of Value-Based Care?

Can Academic Innovation in LDTs Be Halted?
December 30th 2015

Can Academic Innovation in LDTs Be Halted?

LDTs and the Political Wheelhouse
December 30th 2015

LDTs and the Political Wheelhouse

Justifying the Need for FDA Regulation of LDTs
December 30th 2015

Justifying the Need for FDA Regulation of LDTs

Payer and Consumer Response to FDA Regulation of LDTs
December 30th 2015

Payer and Consumer Response to FDA Regulation of LDTs

What Are LDTs and How Are They Regulated?
December 30th 2015

What Are LDTs and How Are They Regulated?

Introduction
December 30th 2015

Introduction

Site Logo
December 30th 2015

Physicians Discover Palbociclib Effective in Cancers Beyond Those of the Breast

Surabhi Dangi-Garimella, PhD
A literature review by researchers at the Abramson Cancer Center has identified a potential use of the cell cycle inhibitor palbociclib in a variety of cancers.
Site Logo
December 30th 2015

Most-Read Articles From AJMC's Conference Coverage in 2015

Surabhi Dangi-Garimella, PhD
Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.
Site Logo
December 29th 2015

Using Technology to Bring Palliative Care to the Patient's Doorstep

Surabhi Dangi-Garimella, PhD
After having launched a palliative care program in 2014, Cambia Health Solutions is now looking for ways to improve patient access to these tools that can improve a patient's quality of life.
Site Logo
December 29th 2015

Cost, Value of Cancer Drugs Take Center Stage in Current Issue of AJMC's Evidence-Based Oncology

One of the biggest stories of 2015 has been the cost of cancer drugs, which create vexing questions for payers and policymakers, as well as doctors and families. The tough choices being made today are the theme of the latest special issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.
Site Logo
December 28th 2015

Improving Cancer Trial Participation via Web-Based Interventions

Surabhi Dangi-Garimella, PhD
Patient awareness and educational support can improve their attitude as well as prepare them to make better informed decisions on clinical trial participation, a new study has found.
Site Logo
December 28th 2015

Report: Shkreli Arrest Prompts Cancer Center to Stop Trial

Mary K. Caffrey
Moffitt Cancer Center said there's nothing wrong with the drug, but a spokesman said the trial is halted for now pending the outcome of the investigation.
Site Logo
December 28th 2015

Cancer's Toll Beyond the Disease: Medical Costs and Productivity

Surabhi Dangi-Garimella, PhD
A new study published by the American Cancer Society found that younger colorectal cancer survivors end up spending over $8500 annually in medical expenses and they also experience significantly greater loss of productivity compared with individuals without cancer.
This Week in Managed Care: December 26, 2015
December 26th 2015

This Week in Managed Care: December 26, 2015

This week The American Journal of Managed Care offers a special episode of highlights from the American Society of Hematology's annual meeting, including sessions on newly approved treatments, how the move to pay-for-performance affects hematologists, and the increasing role of patient-reported outcomes.
Site Logo
December 25th 2015

Most-Viewed Videos from AJMC for the Year 2015

Surabhi Dangi-Garimella, PhD
Top 10 videos from The American Journal of Managed Care's Summit and Insight programs.
Site Logo
December 23rd 2015

Rivaroxaban Safe and Effective in Cancer Patients With Thrombosis

Laura Joszt, MA
Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.
Site Logo
December 22nd 2015

OB-GYN Groups Say Insurers' Genetic Testing Rules Limit Access to Care

Mary K. Caffrey
The statement from the obstetricians and gynecologists said that there aren't enough certified genetic counselors to meet demand. In a statement, the groups said this will limit access to care if patients must wait for assistance before ordering tests.
Site Logo
December 22nd 2015

Top 10 Articles from Evidence-Based Oncology for the Year 2015

Surabhi Dangi-Garimella, PhD
The most read articles in The American Journal of Managed Care's Evidence-Based Oncology ranged from personal narratives to healthcare policy issues that impact the broader population.
This Week in Managed Care: December 19, 2015
December 19th 2015

This Week in Managed Care: December 19, 2015

This week in managed care, Martin Shkreli, CEO of Turing Pharmaceuticals was arrested on charges of fraud; new research find that drug costs continue to take up a larger share of healthcare spending; and 3 healthcare experts take a look at how to fix the 340B drug pricing program.
Site Logo
December 18th 2015

Merck's Pembrolizumab Receives Approval for Expanded Indications

AJMC Staff
Pembrolizumab has been approved as first-line treatment for patients with unresectable or metastatic melanoma.
Site Logo
December 18th 2015

What We're Reading: Taxpayers Spending Millions on Expensive Generic Drugs

AJMC Staff
What we're reading, December 18, 2015: HHS report finds generic drug prices rising faster than inflation; UnitedHealthcare's real-time drug approval tool; and government overcharged by private Medicare Advantage plans.
Site Logo
December 18th 2015

Progress Toward Healthy People 2020: CDC Report Claims Reduction in Cancer Incidence

Surabhi Dangi-Garimella, PhD
Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.
Site Logo
December 18th 2015

FDA Seeks Nationwide Ban on Letting Minors Use Tanning Beds

Mary K. Caffrey
Eleven states already ban minors from using tanning beds, and most states have other restrictions such as requiring a parent's permission.
Site Logo
December 17th 2015

Report Provides an Update on the 340B Drug Pricing Program

Surabhi Dangi-Garimella, PhD
A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.
Site Logo
December 17th 2015

Need to Lower Drug Costs, Not the Size of the Donut Hole, for Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD
A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.
Site Logo
December 16th 2015

Kadcyla and Opdivo Too Expensive for NICE

AJMC Staff
NICE rejects promising oncology agents once again, citing high drug cost.
Site Logo
December 16th 2015

FDA Updates: Oncology

Surabhi Dangi-Garimella, PhD
Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.
Site Logo
December 16th 2015

Managed Care Updates: Oncology

Surabhi Dangi-Garimella, PhD
Updates on screening age recommendations for mammograms, CDC report on a decline in smoking rates in the country, and regulation of laboratory-developed tests.
<1
...
112113114115116117118119120
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo